The UK government’s new life sciences strategy,
The UK government’s new life sciences strategy, aimed at enhancing R&D and expediting medicine regulation, has sparked both support and concern within the pharmaceutical sector.
While GSK and Moderna have welcomed the initiative, unresolved drug pricing issues threaten to dampen the UK’s competitive edge, a concern shared by many industry leaders.
At Kleboe Jardine, we understand how critical supportive frameworks are for fostering growth and innovation. Let’s continue the conversation on how we can collectively drive progress in life sciences.
